Microarray analysis of Lyve1-Cre+ ribosome-associated mRNAs revealed a gene signature indicative of an immune response within the meninges following NTG treatment, including several Th1 and Th2 activation pathways and established serum biomarkers of migraine such as C-related peptide (CRP) and pentraxin3 (PTX3), which supports the model of neuro-vascular-immune crosstalk during migraine responses. The gene discussed is PTX3; the disease is migraine disorder.